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Abstract
Background: In gestational trophoblastic disease, the prognosis is related to the ge-
netic constitution. In some cases, taking a biopsy is contraindicated.
Methods: In a pregnant woman, ultrasound scanning suggested hydatidiform mole. 
To explore if the genetic constitution can be established without taking a biopsy (or 
terminating the pregnancy), cell-free DNA and circulating gestational trophoblasts 
were isolated from maternal blood before evacuation of the uterus. The evacuated 
tissue showed the morphology of a complete hydatidiform mole. Without prior 
whole-genome amplification, short tandem repeat analysis of 24 DNA markers was 
performed on the samples, and on DNA isolated from evacuated tissue, and from the 
blood of the patient and her partner.
Results: Identical genetic results were obtained in each of three circulating gesta-
tional trophoblasts and the evacuated tissue, showing that this conceptus had a diploid 
androgenetic nuclear genome. In contrast, analysis of cell-free DNA was less inform-
ative and less specific due to the inherent presence of cell-free DNA from the patient.
Conclusion: Our results show that it is possible to isolate and analyze circulating 
gestational trophoblasts originating in a pregnancy without maternal nuclear genome. 
For diagnosing gestational trophoblastic diseases, genotyping circulating gestational 
trophoblasts appears to be superior to analysis of cell-free DNA.
K E Y W O R D S
androgenetic, cell-free nucleic acids, circulating neoplasm cells, other circulating cells, diploidy, 
genotyping techniques, gestational trophoblastic disease, hydatidiform mole, liquid biopsy
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1 |  INTRODUCTION
Most hydatidiform moles (HMs) are diploid with both ge-
nome sets originating from the father (parental type: PP), 
or triploid with two genome sets from the father and one 
from the mother (parental type: PPM). Most of the HMs 
with the parental type PP show homozygosity in all loci 
(P1P1), whereas approximately 15% show heterozygos-
ity in some loci (P1P2). HM impose an increased risk of 
gestational trophoblastic neoplasia (GTN) (Niemann et al., 
2007).
Correct diagnosis of gestational trophoblastic diseases is 
the prerequisite for optimal prognostics and treatment. The 
risk of GTN is higher after a diploid HM than after a triploid 
HM (Scholz et al., 2015); and among the diploid HMs, those 
with the parental type P1P2 seem to have the highest risk 
(Khawajkie et al., 2020). Furthermore, more intensive treat-
ment is recommended for trophoblastic neoplasia originating 
in a non-HM pregnancy compared to trophoblastic neoplasia 
originating in a HM (Ngan et al., 2018).
In some cases of gestational trophoblastic disease, it is 
undesirable to take a biopsy. In case of trophoblastic neo-
plasia, the risk of bleeding is high. Similarly, in case of 
multiple pregnancy including a HM, it would be attractive 
to know the genetic constitution of the molar part of the 
pregnancy without performing invasive sampling due to the 
risk of abortion associated with the procedure. Recently it 
has been documented that the genetic constitution of tro-
phoblastic neoplasms can be determined by analyzing DNA 
circulating in the maternal blood (cell-free DNA, cfDNA). 
However, the interpretation of results from such analyses 
is hampered by the inherent presence of maternal DNA in 
the sample (Kristiansen et al., 2016; Openshaw et al., 2015). 
Here, we demonstrate that it is also possible to determine the 
genetic constitution of a HM by analyzing a blood sample 
from the patient, and that analyzing trophoblasts originating 
from the HM and circulating in maternal blood (circulating 
Gestational Trophoblasts, cGTs) may be superior to analyz-
ing cfDNA.
2 |  MATERIALS AND METHODS
2.1 | Ethical compliance
The project was approved by the Danish Data Protection 
Agency (number: 2003-41-3231) and by The Committee for 
Ethics in Science of Central Denmark Region (number: 1-10-
72-370-13). The patient and her partner gave their written 
informed consent.
In a 28-year-old G1P0 woman, routine ultrasound exam-
ination in gestational week 13 + 5 disclosed a 12 × 10 × 8 cm 
mass in the uterus suspected of being a hydatidiform mole. 
Histopathologic examination disclosed morphologic findings 
characteristic for a complete HM.
Immediately before evacuation of the uterus, 30-ml blood 
was drawn from the patient in three tubes (Streck Cell-Free 
DNA BCT®). Trophoblasts were isolated as described pre-
viously (Hatt et al., 2014; Hatt et al., 2014). Briefly, Streck 
tubes were centrifuged. Plasma was removed for analysis of 
cfDNA. The buffy coat and the red blood cell fraction from 
the three tubes were pooled, the cells were fixed in parafor-
maldehyde and red blood cells were lysed. cGTs were en-
riched using Miltenyi's Magnetic Activated Cell Sorting 
(MACS) and stained with a pool of cytokeratin antibodies. 
The enriched and stained cGTs were isolated individually.
The evacuated HM tissue was inspected using a dissection 
microscope (x25) and manually freed from maternal tissue. 
For karyotyping, cells were cultivated from approximately 
15  mg HM tissue. Metaphases were prepared and stained 
with quinacrine mustard using standard techniques.
DNA was prepared from ethylenediaminetetraacetic acid 
(EDTA) blood from the patient and her partner, and from 
HM tissue, respectively, using standard techniques. Prior to 
STR analysis, cGTs were lysed using PrepGEM Universal 
(ZyGEM). No whole-genome amplification was performed.
The origin of the genome in the HM tissue, the individual 
cGTs, and cfDNA was investigated by Short Tandem Repeat 
(STR) analysis using the GlobalFiler™ PCR amplification 
kit (Thermo Fischer Scientific) that targets 24 loci spread 
across the human nuclear genome. The 24-multiplex PCR 
was run according to the manufacturer's recommendations 
with minor changes in thermal cycle number to accommo-
date the low DNA input from cGTs and cfDNA. Capillary 
electrophoresis was performed using an ABI 3500 genetic 
analyzer. Data were analyzed using GeneMapper ID-X soft-
ware (Thermo Fischer Scientific).
The STR profiles of the HM tissue, the cGTs, and the 
cfDNA were compared with the corresponding STR pro-
files of the patient (i.e., the mother) and her partner (i.e., the 
father).
3 |  RESULTS
Chromosome analysis of the HM tissue showed the karyo-
type 46,XX. The results of STR analysis are illustrated in 
Figure 1. The observations in all 24 loci are given in Table 1 
and Figure A1.
In the HM tissue, the PCR product from the AMEL locus 
was specific for the X chromosome and not for the Y chro-
mosome, and no product was observed for the two other Y 
chromosomal loci analyzed, in accordance with the observa-
tion of no Y chromosome by karyotyping. In each of the 21 
autosomal loci, only one allele was observed. Comparing the 
results with the results for the mother and the father disclosed 
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that for all loci, the allele in the HM was identical with an 
allele in the father, and for 17 loci the allele in the HM was 
not present in DNA from the mother, indicating that the HM 
had a homozygous androgenetic nuclear genome (parental 
type P1P1).
For all of the three cGTs, the electropherograms for each 
locus showed an allele identical with the allele identified in 
HM tissue and no other signals. Although the peak heights 
were varying, these alleles were clearly identifiable in all 
cases (Figure 1 and Figure A1).
For the cfDNA, the electropherograms for all loci 
showed peaks indicating the same alleles as identified in 
the mother. For 10/21 autosomal loci, an additional peak 
indicating an allele only present in the father was seen, 
and for further five less informative loci, the results were 
consistent with a paternal allele being present. In six 
F I G U R E  1  Analysis of the STR markers in autosomal loci D22S1045, D5S818, D13S317, D7S820, and SE33.HM tissue: DNA from 
evacuated hydatidiform mole. cGTs 1, 2, and 3: DNA from three gestational trophoblasts circulating in maternal blood. cfDNA: Cell free DNA 
circulating in maternal blood. P: Allele identical with allele in the father, only; consistent with the allele being inherited from the father. *: Allele 
identical with allele in the mother, consistent with the sample being contaminated with DNA from the mother. */P: Allele identical with an allele 
present both in the mother and the father.
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autosomal loci, no signal corresponding to a paternal allele 
was observed.
4 |  DISCUSSION
In a woman with a diploid androgenetic HM, we were able 
to identify the parental origin of the nuclear genome in the 
HM by analyzing cGTs, without performing whole-genome 
amplification.
The main limitation in making genetic diagnoses on 
cGTs is the small number of cells analyzed. In case of mosa-
icism (e.g., one cell line having the parental type PP and the 
other having the normal parental type, PM), cells from one 
cell line, only, may be captured, and thus a PP cell line may 
be overlooked. Similarly, in case of twinning, one concep-
tus being a HM, trophoblasts from the non-molar placenta, 
only, may be captured. Therefore, the result interpretation 
should take the morphology (e.g., obtained by ultrasound) 
into consideration. If a HM is suspected and the parental type 
PM, only, is identified in cGTs, one should consider the more 
rare diagnoses, such as multiple pregnancy, mosaicism, and 
even the rare HMs with the parental type PM, which are seen 
in women with biallelic inactivation of NLRP7 or KHDC3L. 
Another limitation of the method is that only 1–2 polymor-
phic loci on each of 20 chromosomes are analyzed; therefore, 
this method cannot detect all types of unusual karyotype.
Compared to analyzing the parental origin in cfDNA, one 
major advantage of analyzing cGTs is the absence of mater-
nal DNA, simplifying the interpretation of the results sig-
nificantly. In addition, the number of loci showing a signal 
representing the gestation was correspondingly higher.
It is important to correctly differentiate between triploid 
and diploid HMs, as the diploid HMs with an androgenetic 
(PP) cell line impose a high risk of gestational trophoblastic 
disease (Niemann et al., 2007). By far most triploid HMs 
show the parental type P1P2M, that is, heterozygosity for 
paternal alleles (Scholz et al., 2015), and thus a triploid HM 
T A B L E  1  Allelles observed by DNA marker analysis using the GlobalFiler™ kit






tissue cGT 1 cGT 2 cGT 3 cfDNA1
D3S1358 3p21.31 16 15.17 16 16 16 16 ?,15,(16),17
vWA 12p13.31 14.17 14.18 14 14 14 14 14,18
D16S539 16q24.1 9.12 10.11 12 12 12 12 10,11,(12)
CSF1PO 5q33.3-34 10.11 12.13 10 10 10 10 12,13
TPOX 2p23-2per 9.11 8 11 11 11 11 8, (11)
Y indel Yq11.221 2 NS NS NS NS NS NS
AMEL X: p22.1-22.3
Y: p11.2
X,Y X X X X X X
D8S1179 8q24.13 11.12 10.13 11 11 11 11 10,(11),13
D21S11 21q11.2-q21 29 30,32.2 29 29 29 29 (29),30,32.2
D18S51 18q21.33 13.19 15.18 13 13 13 13 (13),15,18
DYS391 Yq11.21 10 NS NS NS NS NS NS
D2S441 2p14 11.14 11.14 14 14 14 14 (11),?,14
D19S433 19q12 12.16 13.14 16 16 16 16 13,14,(16)
TH01 11p15.5 9.3 9.3 9.3 9.3 9.3 9.3 9.3
FGA 4q28 22.25 21.23 25 25 25 25 21,23,(25)
D22S1045 22q12.3 15.16 11.15 15 15 15 15 11,15
D5S818 5q21-31 11.13 12.13 11 11 11 11 (11),12,13
D13S317 13q22-31 11.12 8 12 12 12 12 8
D7S820 7q11.21-22 10.12 11 10 10 10 10 11
SE33 6q14 25.2,31.2 18,23.2 25.2 25.2 25.2 25.2 18,23.2
D10S1248 10q26.3 14.15 13.15 14 14 14 14 13,(14),15
D1S1656 1q42.2 12,15.3 16.17 12 12 12 12 16,17
D12S391 12p13.2 17 17.23 17 17 17 17 17,23
D2S1338 2q35 20.24 17.19 24 24 24 24 17,19
Note:: 1: Brackets indicate that the peak had a lower height. Allele underlined is identical with an allele in the father.
Abbreviations: ?, A peak with a position and shape suggesting an artifact; NS, No signal.
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is expected to show three alleles in several loci. However, 
in many HMs showing mosaicism including a PP cell line, 
for example, parental type P1P1/P2M or P1P2/PxM, anal-
ysis of DNA from a tissue sample disclose one maternal 
and two paternal alleles in many loci (Sunde et al., 2011). 
Thus, in a marker analysis performed on DNA prepared 
from tissue, with such a mixture of cells, discrimination be-
tween a triploid HM and a diploid HM showing mosaicism 
is problematic. And it would be correspondingly difficult 
in cfDNA.
By analysis of DNA markers in individual cells, this 
problem should be alleviated: In all cells from a triploid HM, 
some loci should show one maternal and two paternal alleles. 
In contrast, no cell from a HM showing mosaicism PP/PM 
should show more than two alleles.
Our data show that the procedure to identify circulating 
cells from conceptuses with a biparental genome can be used 
for identifying cells from a HM with nuclear genome exclu-
sively inherited from the father.
We have previously shown that circulating trophoblasts 
can be isolated from pregnancies in gestational weeks 10–14 
for use in cell-based non-invasive prenatal testing (cbNIPT). 
In a study on 111 pregnancies, we isolated 1–45 (average 12.8) 
trophoblasts from 30 ml of blood (Kolvraa et al., 2016). The 
quality of the DNA from these cells allows for a full-genomic 
DNA analysis and for calling of small copy number variants 
(Kolvraa et al., 2016; Vestergaard et al., 2017; Vossaert et al., 
2019). These circulating cells are expected to be extra-villous 
trophoblasts (EVTs) migrating from the placental villous to 
line the spiral arteries in the placenta (Hatt et al., 2014).
This is the first HM analyzed, therefore, we do not know 
the success rate of analyzing cGTs from HMs. As it has been 
shown that endovascular EVT invasion is reduced in com-
plete HMs, one could expect that fewer cells might reach the 
maternal blood (Sebire et al., 2001). However, Moser et al. 
(2017), have suggested that circulating trophoblasts originate 
from both invaded uterine arteries, veins, and glands, which 
could lead to trophoblasts from complete HMs still ending up 
in the maternal circulation.
Among patients with GTN, Openshaw et al. managed 
to make a genetic diagnosis by analyzing cfDNA in 12/20 
patients (Openshaw et al., 2015). Possibly, analysis of cGTs 
will allow accurate genetic diagnosis in a higher fraction of 
women with GTN, where a biopsy is not available. Similarly, 
this technique may be useful in women with multiple preg-
nancies including a HM, where taking a biopsy is relatively 
contraindicated.
5 |  CONCLUSION
For determining the genetic constitution in hydatidiform 
moles and other gestational diseases by analysis of maternal 
blood, analysis of circulating gestational trophoblasts ap-
pears to be superior to analysis of cell-free DNA.
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APPENDIX A
F I G U R E  A 1  DNA marker analysis using the GlobalFiler™ kit. HM tissue: DNA from evacuated hydatidiform mole. cGTs 1, 2, and 3: DNA 
from three gestational trophoblasts circulating in maternal blood. cfDNA: Cell free DNA circulating in maternal blood. P: Allele identical with 
allele in the father, only; consistent with the allele being inherited from the father. *: Allele identical with allele in the mother, consistent with the 
sample being contaminated with DNA from the mother. */P: Allele identical with an allele present both in the mother and the father
